In treated canines, elevated SPARC was not seen, indicating that SPARC can serve as a valuable biomarker in identifying spondylomyelopathy [1]. Complement C3 is also seen to be elevated in causing degenerative changes leading to myelopathies [1]. Here, SPARC is linked to Myelopathy.